MedTrace Logo

Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer

NCT02209441 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2014-08-06

No results posted yet for this study

Summary

* To determine the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of sorafenib in combination with FOLFOX4 (oxaliplatin/leucovorin/5-fluorouracil) as first-line treatment for advanced gastric cancer
* The design of the study incorporated a standard 3 + 3 dose escalation procedure to guide elevation of the sorafenib dosage to the next level

Conditions

  • Gastric Cancer.

Interventions

DRUG

Phase I Dose-finding Study of Sorafenib Study

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02209441 on ClinicalTrials.gov